Contact Us
Amicus Therapeutics

Senior Management Team

  John F. Crowley, J.D., M.B.A.
President and Chief Executive Officer

Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.

Mr. Crowley is involved with several charitable and community organizations, including serving as president of the National Tay-Sachs and Allied Diseases Association. He is also on the Research Advisory Board of the national Muscular Dystrophy Association and the Board of Directors of St. Peter’s University Hospital. Mr. Crowley’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show.

Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).

Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.
  Donald J. Hayden, Jr.
Executive Chairman

Donald J. Hayden, Jr. brings to Amicus the experiences, insights and perspective gained during a highly successful 25-year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company, including 15 years in senior executive positions. Mr. Hayden has a proven track record of innovative strategy development, growing successful products and businesses and building exceptional leadership teams.

Mr. Hayden began his career as a business intern with Bristol-Myers Squibb in 1981. His early career experiences included serving as director of new business development and planning for the U.S. Pharmaceutical Group, as director of marketing for Mead Johnson Pharmaceuticals and as a district sales manager within the BMS oncology division. Since 1991 Mr. Hayden has held a number of senior management positions including vice president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy, e-business, Investor Relations and Competitive Intelligence; and executive vice president of the Health Care Group. For the past four years, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing.

Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.
  Matthew R. Patterson
Chief Operating Officer

Mr. Patterson joined Amicus in December 2004 and currently serves as Chief Operating Officer. Mr. Patterson was promoted to Chief Operating Officer from Chief Business Officer in September 2006. Prior to Amicus, Mr. Patterson served as vice president of Regulatory Affairs, and later vice president of Commercial Planning at BioMarin Pharmaceutical. Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing function for the company. Prior to BioMarin, Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. While at Genzyme he contributed to the development and global licensing of multiple products.

Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.
  James E. Dentzer
Chief Financial Officer

Mr. Dentzer joined Amicus in September 2006 as Chief Financial Officer.  He joined the company from Biogen Idec Inc. where he served as Corporate Controller from November 2003 to September 2006.  Prior to the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation, Mr. Dentzer served as Corporate Controller of Biogen, Inc.  Prior to Biogen, he served in a variety of financial positions at E. I. du Pont de Nemours and Company, most recently as Chief Financial Officer of DuPont Flooring Systems.  Prior to joining DuPont, Mr. Dentzer held various positions at Kemper Financial Services and Bank of Boston.

Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago.

  David J. Lockhart, Ph.D.
Chief Scientific Officer

Dr. David Lockhart joined Amicus Therapeutics in January 2006 as chief scientific officer. He brings to Amicus 13 years of industry experience and achievements including credit as the primary developer of genome-wide gene-expression profiling with high-density DNA arrays when he was at Affymetrix.

Before coming to Amicus, Dr. Lockhart was president, CSO and co-founder of Ambit Biosciences in San Diego. He has served as director of genomics at the Genomics Institute of the Novartis Research Foundation, and he held various leadership positions during his more than five years at Affymetrix, including vice president of genomics research. Dr. Lockhart has also been a visiting scholar at the Salk Institute for Biological Studies.

Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at MIT under Professor Peter S. Kim. He has published nearly 60 peer-reviewed scientific articles on kinase technology, kinase inhibitor discovery, genomics and the use of genomic tools for important biological and biomedical problems.


David Palling, Ph.D.
Senior Vice President, Drug Development

Dr. Palling brings more than 20 years of drug development experience to Amicus and has served as senior vice president of Drug Development since the company began operations in August 2002.  He has responsibility for preclinical development and manufacturing.  Previously, he was vice president of Worldwide Assay Research and Development at Ortho Clinical Diagnostics, a Johnson & Johnson Company, and prior to that he served as senior director of Pharmaceutical Development at Johnson & Johnson Pharmaceutical Research and Development.

Prior to Johnson & Johnson, Dr. Palling worked at Hoffmann-La Roche where he held various management positions within Pharmaceutical Development. He was head of Analytical Research and Development, as well as an International Project Director leading multi-functional teams developing new medicines, primarily for oncology and virology.

Dr. Palling received B.Sc. and Ph.D. degrees in Chemistry from the University of London, King's College, and conducted post-doctoral research in Biochemistry at Brandeis University.
  Karin Ludwig, M.D.
Senior Vice President, Clinical Research

Dr. Karin Ludwig joined Amicus Therapeutics in February 2006 and brings more than 15 years of medical experience to her position as senior vice president of Clinical Research.

Dr. Ludwig began her industry career at Farmitalia Carlo Erba in her native Germany. In 1993 she became head of clinical research at Pharmacia in Erlangen, Germany, and held various positions in research and development at Pharmacia & Upjohn and Pharmacia in the U.S. and the U.K. through their acquisition by Pfizer in 2003. At Pfizer she held the position of group leader and senior director of endocrinology and ophthalmology for the U.S. medical program.

Dr. Ludwig received her medical degree from Freiburg University and trained in general surgery at the University Hospital in Tuebingen, Germany.
  Gregory P. Licholai, M.D.
Vice President, Medical Affairs

Dr. Licholai brings his experience in financing medical innovation, in clinical practice and in scientific research to his position overseeing Medical Affairs at Amicus. Prior to joining Amicus in 2004, he was a venture capitalist at Domain Associates, where he helped fund biotechnology and medical device start-up companies. Previously he was director of Ventures and Business Development for Medtronic Neurological, where he managed a global portfolio of novel drug delivery and neurological treatments for diseases such as Parkinson's disease, epilepsy, CNS malignancies and chronic pain syndromes.

Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. During his residency, Dr. Licholai also worked on hospital efficiency and merger strategies for Integral Consulting. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He did research in molecular genetics at Yale University and examined variants in hereditary blood diseases. Dr. Licholai also worked in molecular oncology at Rockefeller University. Additionally, while at Harvard Business School, he worked with Novartis and Millennium Pharmaceuticals. Dr. Licholai received his B.S. from Boston College and Pre-Medical studies at Columbia University, his M.D. from Yale Medical School and his M.B.A from Harvard Business School.
  Douglas A. Branch
Vice President, General Counsel and Secretary

Mr. Branch joined Amicus as General Counsel and Secretary in December 2005 and became Vice President in May 2006. He has more than 20 years of experience in securities, corporate and high technology law. Prior to joining Amicus, Mr. Branch was President of Biotech Law Associates, P.C., a law firm representing emerging life science companies, and before founding that firm, he was a Director and Shareholder in Phillips McFall McCaffrey McVay & Murrah, P.C., an Oklahoma City law firm. He is the former Chairman of the Oklahoma Center for the Advancement of Science and Technology.

Mr. Branch holds B.B.A. (Finance) and J.D. degrees from the University of Oklahoma.

  S. Nicole Schaeffer
Senior Vice President, Human Resources & Leadership Development

Nicole Schaeffer has overseen Human Resources and Leadership Development at Amicus since March 2005. She brings over five years of experience building talent at early stage biotechnology companies. Prior to joining Amicus, Ms. Schaeffer worked at Flagship Ventures helping to start several high-tech/biotech companies including Compound Therapeutics, Epitome Biosystems and BG Medicine.

Ms. Schaeffer then served as Director and later Senior Director of Human Resources for all three firms, responsible for all HR functions. Preceding her work with Flagship Ventures, Ms. Schaeffer rose from Manager to Director of Human Resources, responsible for all HR functions for Oak Industries, Inc., a publicly traded $450 million supplier of components to the communications industry. Ms. Schaeffer has also held a variety of human resources positions at the EMC Corporation.

Ms. Schaeffer received her B.A. from the University of Rochester and her M.B.A. from Boston University.